Less than a month after partner Glaxosmithkline plc (GSK) offered good phase III news with the would-be blockbuster shingles therapy HZ/su exploiting Agenus Inc.'s QS-21 Stimulon adjuvant, Agenus disclosed a new arrangement with Incyte Corp. to investigate checkpoint modulators in onco-immunology, by way of a deal similar to – but much broader than – an earlier pact with Merck & Co. Inc.